Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy.

2. To evaluate toxicity, the initial local-regional control rate, sites of and time to local and distant failures.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Cisplatin; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

1. No previous treatment.

2. Tumor must be resectable.

3. >/= 18 and

4. Zubrod performance status

5. Must have adequate bone marrow, liver and renal function as defined in 3.6.

Exclusion Criteria:

1. Cytological or histological proof of N3 disease.

2. Evidence of metastatic disease to distant sites.

3. Patients with impending cord compression will be ineligible.